Search for "imidazoles" in Full Text gives 72 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2016, 12, 1911–1924, doi:10.3762/bjoc.12.181
Graphical Abstract
Scheme 1: The transesterification of diethyl oxalate (DEO) with phenol catalyzed by MoO3/SiO2.
Scheme 2: Transesterification of a triglyceride (TG) with DMC for biodiesel production using KOH as the base ...
Scheme 3: Top: Green methylation of phosphines and amines by dimethyl carbonate (Q = N, P). Bottom: anion met...
Figure 1: Structures of some representative SILs and PILs systems. MCF is a silica-based mesostructured mater...
Scheme 4: Synthesis of the acid polymeric IL. EGDMA: ethylene glycol dimethacrylate.
Scheme 5: The transesterification of sec-butyl acetate with MeOH catalyzed by some acidic imidazolium ILs.
Figure 2: Representative examples of ionic liquids for biodiesel production.
Scheme 6: Top: phosgenation of methanol; middle: EniChem and Ube processes; bottom: Asahi process for the pro...
Scheme 7: The transesterification in the synthesis of organic carbonates.
Scheme 8: The transesterification of DMC with alcohols and diols.
Scheme 9: Transesterification of glycerol with DMC in the presence of 1-n-butyl-3-methylimidazolium-2-carboxy...
Scheme 10: Synthesis of the BMIM-2-CO2 catalyst from butylimidazole and DMC.
Scheme 11: Plausible cooperative (nucleophilic–electrophilic) mechanism for the transesterification of glycero...
Scheme 12: Synthesis of diazabicyclo[5.4.0]undec-7-ene-based ionic liquids.
Scheme 13: Synthesis of the DABCO–DMC ionic liquid.
Scheme 14: Cooperative mechanism of ionic liquid-catalyzed glycidol production.
Scheme 15: [TMA][OH]-catalyzed synthesis of glycidol (GD) from glycerol and dimethyl carbonate [46].
Scheme 16: [BMIM]OH-catalyzed synthesis of DPC from DMC and 1-pentanol.
Figure 3: Representative examples of ionic liquids for biodiesel production.
Figure 4: Acyclic non-symmetrical organic carbonates synthetized with 1-(trimethoxysilyl)propyl-3-methylimida...
Scheme 17: A simplified reaction mechanism for DMC production.
Scheme 18: [P8881][MeOCO2] metathesis with acetic acid and phenol.
Figure 5: Examples of carbonates obtained through transesterification using phosphonium salts as catalysts.
Scheme 19: Examples of carbonates obtained from different bio-based diols using [P8881][CH3OCO2] as catalyst.
Scheme 20: Ambiphilic catalysis for transesterification reactions in the presence of carbonate phosphonium sal...
Beilstein J. Org. Chem. 2015, 11, 2223–2241, doi:10.3762/bjoc.11.241
Graphical Abstract
Figure 1: Some ruthenium catalysts for metathesis reactions.
Scheme 1: Decomposition of methylidenes 1 and 2.
Scheme 2: Deactivation of G-HII in the presence of ethylene.
Scheme 3: Reaction between GI/GII and n-BuNH2.
Scheme 4: Reaction of GII with amines a–d.
Scheme 5: Amine-induced decomposition of GII methylidene 2.
Scheme 6: Amine-induced decomposition of GII in RCM conditions.
Scheme 7: Deactivation of methylidene 2 in the presence of pyridine.
Scheme 8: Reaction of G-HII with various amines.
Scheme 9: Formation of olefin 22 from styrene.
Scheme 10: Hypothetic deactivation pathway of G-HII.
Scheme 11: RCM of dienic pyridinium salts.
Scheme 12: Synthesis of polycyclic scaffolds using RCM.
Scheme 13: Enyne ring-closing metathesis.
Scheme 14: Synthesis of (R)-(+)-muscopyridine using a RCM strategy.
Scheme 15: Synthesis of a tris-pyrrole macrocycle.
Scheme 16: Synthesis of a bicyclic imidazole.
Scheme 17: RCM using Schrock’s catalyst 44.
Scheme 18: Synthesis of 1,6-pyrido-diazocine 46 by using a RCM.
Scheme 19: Synthesis of fused pyrimido-azepines through RCM.
Scheme 20: RCM involving alkenes containing various N-heteroaromatics.
Scheme 21: Synthesis of dihydroisoquinoline using a RCM.
Scheme 22: Formation of tricyclic compound 59.
Scheme 23: RCM in the synthesis of normuscopyridine.
Scheme 24: Synthesis of macrocycle 64.
Scheme 25: Synthesis of macrocycles possessing an imidazole group.
Scheme 26: Retrosynthesis of an analogue of erythromycin.
Scheme 27: Retrosynthesis of haminol A.
Scheme 28: CM involving 3-vinylpyridine 70 with 71 and vinylpyridine 70 with 73.
Scheme 29: Revised retrosynthesis of haminol A.
Scheme 30: CM between 78 and crotonaldehyde.
Scheme 31: Hypothesized deactivation pathway.
Scheme 32: CM involving an allyl sulfide containing a quinoline.
Scheme 33: CM involving allylic sulfide possessing a quinoxaline or a phenanthroline.
Scheme 34: CM between an acrylate and a 2-methoxy-5-bromo pyridine.
Scheme 35: Successful CM of an alkene containing a 2-chloropyridine.
Scheme 36: Variation of the substituent on the pyridine ring.
Scheme 37: CM involving alkenes containing a variety of N-heteroaromatics.
Beilstein J. Org. Chem. 2015, 11, 2209–2222, doi:10.3762/bjoc.11.240
Graphical Abstract
Scheme 1: Copper-catalyzed C–H amidation of tertiary amines.
Scheme 2: Copper-catalyzed C–H amidation and sulfonamidation of tertiary amines.
Scheme 3: Copper-catalyzed sulfonamidation of allylic C–H bonds.
Scheme 4: Copper-catalyzed sulfonamidation of benzylic C–H bonds.
Scheme 5: Copper-catalyzed sulfonamidation of C–H bonds adjacent to oxygen.
Scheme 6: Copper-catalyzed amidation and sulfonamidation of inactivated alkyl C–H bonds.
Scheme 7: Copper-catalyzed amidation and sulfonamidation of inactivated alkanes.
Scheme 8: Copper-catalyzed intramolecular C–H amidation for lactam synthesis.
Scheme 9: Copper-catalyzed intramolecular C–H amidation for lactam synthesis.
Scheme 10: Copper-catalyzed amidation/sulfonamidation of aryl C–H bonds.
Scheme 11: C–H amidation of pyridinylbenzenes and indoles.
Scheme 12: Mechanism of the Cu-catalyzed C2-amidation of indoles.
Scheme 13: Copper-catalyzed, 2-phenyl oxazole-assisted C–H amidation of benzamides.
Scheme 14: DG-assisted amidation/imidation of indole and benzene C–H bonds.
Scheme 15: Copper-catalyzed C–H amination/amidation of quinoline N-oxides.
Scheme 16: Copper-catalyzed aldehyde formyl C–H amidation.
Scheme 17: Copper-catalyzed formamide C–H amidation.
Scheme 18: Copper-catalyzed sulfonamidation of vinyl C–H bonds.
Scheme 19: CuCl2-catalyzed amidation/sulfonamidation of alkynyl C–H bonds.
Scheme 20: Cu(OH)2-catalyzed amidation/sulfonamidation of alkynyl C–H bonds.
Scheme 21: Sulfonamidation-based cascade reaction for the synthesis of tetrahydrotriazines.
Scheme 22: Copper-catalyzed cascade reaction for the synthesis of quinazolinones.
Scheme 23: Copper-catalyzed cascade reactions for the synthesis of fused quinazolinones.
Scheme 24: Copper-catalyzed synthesis of quinazolinones via methyl C–H bond amidation.
Scheme 25: Dicumyl peroxide-based cascade synthesis of quinazolinones.
Scheme 26: Copper-catalyzed cascade reactions for the synthesis of indolinones.
Beilstein J. Org. Chem. 2015, 11, 2021–2028, doi:10.3762/bjoc.11.219
Graphical Abstract
Figure 1: Formation of substituted aziridine.
Figure 2: Various strategies for the formation of 2H-azirine.
Scheme 1: Attempted reaction for the synthesis of 3a.
Figure 3: Synthesis of α-amido-1,3-diketone (3a–o). Reaction conditions: α-azidochalcone 1 (1.0 equiv) and ca...
Scheme 2: Plausible mechanism.
Scheme 3: Attempted reaction with acid derivatives.
Scheme 4: Oxazole formation from 3.
Figure 4: Possible isomers for 7.
Scheme 5: Oxazole formation.
Figure 5: Synthesis of highly substituted 2-(trifluoromethyl)oxazoles (8a–e). Reaction conditions: α-azidocha...
Scheme 6: Mechanism for the formation of 8.
Beilstein J. Org. Chem. 2015, 11, 1732–1740, doi:10.3762/bjoc.11.189
Graphical Abstract
Scheme 1: The formation and possible tautomeric equilibria of 2-methoxycarbonyl- and 2-carboxy-3-(1H-imidazol...
Scheme 2: FeCl2/Et3N-catalyzed domino sequence leading to 5-alkoxycarbonylpyrrol-3-ylimidazolium salts 1.
Scheme 3: The synthesis of methyl 4-(1H-imidazol-1-yl)-1H-pyrrole-2-carboxylates 12.
Scheme 4: The hydrolysis of ylide 2a and bromide 1b.
Figure 1: Molecular structure of compound 6b (CCDC 1406417). Carbon, nitrogen and oxygen atoms are grey, blue...
Beilstein J. Org. Chem. 2014, 10, 2903–2911, doi:10.3762/bjoc.10.308
Graphical Abstract
Figure 1: Phase solubility diagrams for fluconazole obtained with β-cyclodextrin derivatives at 25 °C in wate...
Figure 2: Solubility of fluconazole in aqueous solutions containing 5% of CD and 0.5% of the respective polys...
Figure 3: Ocular cytotoxicity studies of HPBCD and SBECD in primary corneal human keratocytes, using real-tim...
Figure 4: Ocular cytotoxicity studies of fluconazole in primary corneal human keratocytes obtained using real...
Figure 5: HET-CAM assay: (a) positive Control (NaOH 0.1 N); (b) negative control (NaCl 0.9%); (c) HPBCD 10 mg...
Figure 6: Bioadhesive properties (bioadhesion work and maximum force of detachment) of ion-sensitive hydrogel...
Figure 7: Release profiles of fluconazole in simulated tear fluid from the gels with (closed symbols) or with...
Beilstein J. Org. Chem. 2014, 10, 1413–1420, doi:10.3762/bjoc.10.145
Graphical Abstract
Scheme 1: Synthesis of 2-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1H-benzo[d]imidazoles.
Scheme 2: Plausible mechanism for the synthesis of 2-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1H-b...
Beilstein J. Org. Chem. 2014, 10, 481–513, doi:10.3762/bjoc.10.46
Graphical Abstract
Scheme 1: General reaction mechanism for Ag(I)-catalyzed A3-coupling reactions.
Scheme 2: A3-coupling reaction catalyzed by polystyrene-supported NHC–silver halides.
Figure 1: Various NHC–Ag(I) complexes used as catalysts for A3-coupling.
Scheme 3: Proposed reaction mechanism for NHC–AgCl catalyzed A3-coupling reactions.
Scheme 4: Liu’s synthesis of pyrrole-2-carboxaldehydes 4.
Scheme 5: Proposed reaction mechanism for Liu’s synthesis of pyrrole-2-carboxaldehydes 4.
Scheme 6: Gold-catalyzed synthesis of propargylamines 1.
Scheme 7: A3-coupling catalyzed by phosphinamidic Au(III) metallacycle 6.
Scheme 8: Gold-catalyzed KA2-coupling.
Scheme 9: A3-coupling applied to aldehyde-containing oligosaccharides 8.
Scheme 10: A3-MCR for the preparation of propargylamine-substituted indoles 9.
Scheme 11: A3-coupling interceded synthesis of furans 12.
Scheme 12: A3/KA2-coupling mediated synthesis of functionalized dihydropyrazoles 13 and polycyclic dihydropyra...
Scheme 13: Au(I)-catalyzed entry to cyclic carbamimidates 17 via an A3-coupling-type approach.
Scheme 14: Proposed reaction mechanism for the Au(I)-catalyzed synthesis of cyclic carbamimidates 17.
Figure 2: Chiral trans-1-diphenylphosphino-2-aminocyclohexane–Au(I) complex 20.
Scheme 15: A3-coupling-type synthesis of oxazoles 21 catalyzed by Au(III)–salen complex.
Scheme 16: Proposed reaction mechanism for the synthesis of oxazoles 21.
Scheme 17: Synthesis of propargyl ethyl ethers 24 by an A3-coupling-type reaction.
Scheme 18: General mechanism of Ag(I)-catalyzed MCRs of 2-alkynylbenzaldehydes, amines and nucleophiles.
Scheme 19: General synthetic pathway to 1,3-disubstituted-1,2-dihydroisoquinolines.
Scheme 20: Synthesis of 1,3-disubstituted-1,2-dihydroisoquinolines 29.
Scheme 21: Synthesis of 1,3-disubstituted-1,2-dihydroisoquinolines 35 and 36.
Scheme 22: Rh(II)/Ag(I) co-catalyzed synthesis of 1,3-disubstituted-1,2-dihydroisoquinolines 40.
Scheme 23: General synthetic pathway to 2-amino-1,2-dihydroquinolines.
Scheme 24: Synthesis of 2-amino-1,2-dihydroquinolines 47.
Scheme 25: Synthesis of tricyclic H-pyrazolo[5,1-a]isoquinoline 48.
Scheme 26: Synthesis of tricyclic H-pyrazolo[5,1-a]isoquinolines 48.
Scheme 27: Cu(II)/Ag(I) catalyzed synthesis of H-pyrazolo[5,1-a]isoquinolines 48.
Scheme 28: Synthesis of 2-aminopyrazolo[5,1-a]isoquinolines 53.
Scheme 29: Synthesis of 1-(isoquinolin-1-yl)guanidines 55.
Scheme 30: Ag(I)/Cu(I) catalyzed synthesis of 2-amino-H-pyrazolo[5,1-a]isoquinolines 58.
Scheme 31: Ag(I)/Ni(II) co-catalyzed synthesis of 3,4-dihydro-1H-pyridazino[6,1-a]isoquinoline-1,1-dicarboxyla...
Scheme 32: Ag(I) promoted activation of the α-carbon atom of the isocyanide group.
Scheme 33: Synthesis of dihydroimidazoles 65.
Scheme 34: Synthesis of oxazoles 68.
Scheme 35: Stereoselective synthesis of chiral butenolides 71.
Scheme 36: Proposed reaction mechanism for the synthesis of butenolides 71.
Scheme 37: Stereoselective three-component approach to pirrolidines 77 by means of a chiral auxiliary.
Scheme 38: Stereoselective three-component approach to pyrrolidines 81 and 82 by means of a chiral catalyst.
Scheme 39: Synthesis of substituted five-membered carbocyles 86.
Scheme 40: Synthesis of regioisomeric arylnaphthalene lactones.
Scheme 41: Enantioselective synthesis of spiroacetals 96 by Fañanás and Rodríguez [105].
Scheme 42: Enantioselective synthesis of spiroacetals 101 by Gong [106].
Scheme 43: Synthesis of polyfunctionalized fused bicyclic ketals 103 and bridged tricyclic ketals 104.
Scheme 44: Proposed reaction mechanism for the synthesis of ketals 103 and 104.
Scheme 45: Synthesis of β-alkoxyketones 108.
Scheme 46: Synthesis of N-methyl-1,4-dihydropyridines 112.
Scheme 47: Synthesis of tetrahydrocarbazoles 115–117.
Scheme 48: Plausible reaction mechanism for the synthesis of tetrahydrocarbazoles 115–117.
Scheme 49: Carboamination, carboalkoxylation and carbolactonization of terminal alkenes.
Scheme 50: Oxyarylation of alkenes with arylboronic acids and Selectfluor as reoxidant.
Scheme 51: Proposed reaction mechanism for oxyarylation of alkenes.
Scheme 52: Oxyarylation of alkenes with arylsilanes and Selectfluor as reoxidant.
Scheme 53: Oxyarylation of alkenes with arylsilanes and IBA as reoxidant.
Beilstein J. Org. Chem. 2013, 9, 2476–2536, doi:10.3762/bjoc.9.287
Graphical Abstract
Scheme 1: Pd-catalyzed monofluoromethylation of pinacol phenylboronate [44].
Scheme 2: Cu-catalyzed monofluoromethylation with 2-PySO2CHFCOR followed by desulfonylation [49].
Scheme 3: Cu-catalyzed difluoromethylation with α-silyldifluoroacetates [57].
Figure 1: Mechanism of the Cu-catalyzed C–CHF2 bond formation of α,β-unsaturated carboxylic acids through dec...
Scheme 4: Fe-catalyzed decarboxylative difluoromethylation of cinnamic acids [62].
Scheme 5: Preliminary experiments for investigation of the mechanism of the C–H trifluoromethylation of N-ary...
Figure 2: Plausible catalytic cycle proposed by Z.-J. Shi et al. for the trifluoromethylation of acetanilides ...
Figure 3: Plausible catalytic cycle proposed by M. S. Sanford et al. for the perfluoroalkylation of simple ar...
Figure 4: Postulated reaction pathway for the Ag/Cu-catalyzed trifluoromethylation of aryl iodides by Z. Q. W...
Figure 5: Postulated reaction mechanism for Cu-catalyzed trifluoromethylation reaction using MTFA as trifluor...
Scheme 6: Formal Heck-type trifluoromethylation of vinyl(het)arenes by M. Sodeoka et al. [83].
Figure 6: Proposed catalytic cycle for the copper-catalyzed trifluoromethylation of (het)arenes in presence o...
Figure 7: Proposed catalytic cycle for the copper-catalyzed trifluoromethylation of N,N-disubstituted (hetero...
Figure 8: Proposed catalytic cycle by Y. Zhang and J. Wang et al. for the copper-catalyzed trifluoromethylati...
Figure 9: Mechanistic rationale for the trifluoromethylation of arenes in presence of Langlois’s reagent and ...
Scheme 7: Trifluoromethylation of 4-acetylpyridine with Langlois’s reagent by P. S. Baran et al. (* Stirring ...
Scheme 8: Catalytic copper-facilitated perfluorobutylation of benzene with C4F9I and benzoyl peroxide [90].
Figure 10: F.-L. Qing et al.’s proposed mechanism for the copper-catalyzed trifluoromethylation of (hetero)are...
Figure 11: Mechanism of the Cu-catalyzed/Ru-photocatalyzed trifluoromethylation and perfluoroalkylation of ary...
Figure 12: Proposed mechanism for the Cu-catalyzed trifluoromethylation of aryl- and vinyl boronic acids with ...
Figure 13: Possible mechanism for the Cu-catalyzed decarboxylative trifluoromethylation of cinnamic acids [62].
Scheme 9: Ruthenium-catalyzed perfluoroalkylation of alkenes and (hetero)arenes with perfluoroalkylsulfonyl c...
Figure 14: N. Kamigata et al.’s proposed mechanism for the Ru-catalyzed perfluoroalkylation of alkenes and (he...
Figure 15: Proposed mechanism for the Ru-catalyzed photoredox trifluoromethylation of (hetero)arenes with trif...
Figure 16: Late-stage trifluoromethylation of pharmaceutically relevant molecules with trifluoromethanesulfony...
Figure 17: Proposed mechanism for the trifluoromethylation of alkenes with trifluoromethyl iodide under Ru-bas...
Scheme 10: Formal perfluoroakylation of terminal alkenes by Ru-catalyzed cross-metathesis with perfluoroalkyle...
Figure 18: One-pot Ir-catalyzed borylation/Cu-catalyzed trifluoromethylation of complex small molecules by Q. ...
Figure 19: Mechanistic proposal for the Ni-catalyzed perfluoroalkylation of arenes and heteroarenes with perfl...
Scheme 11: Electrochemical Ni-catalyzed perfluoroalkylation of 2-phenylpyridine (Y. H. Budnikova et al.) [71].
Scheme 12: Fe(II)-catalyzed trifluoromethylation of arenes and heteroarenes with trifluoromethyl iodide (T. Ya...
Figure 20: Mechanistic proposal by T. Yamakawa et al. for the Fe(II)-catalyzed trifluoromethylation of arenes ...
Scheme 13: Ytterbium-catalyzed perfluoroalkylation of dihydropyran with perfluoroalkyl iodide (Y. Ding et al.) ...
Figure 21: Mechanistic proposal by A. Togni et al. for the rhenium-catalyzed trifluoromethylation of arenes an...
Figure 22: Mechanism of the Cu-catalyzed oxidative trifluoromethylthiolation of arylboronic acids with TMSCF3 ...
Scheme 14: Removal of the 8-aminoquinoline auxiliary [136].
Figure 23: Mechanism of the Cu-catalyzed trifluoromethylthiolation of C–H bonds with a trifluoromethanesulfony...
Beilstein J. Org. Chem. 2013, 9, 2463–2469, doi:10.3762/bjoc.9.285
Graphical Abstract
Figure 1: Representative biologically relevant examples of 5,6-dihydroindolo[1,2-a]quinoxaline derivatives.
Scheme 1: Reagents and conditions: (a) CF3COOH, anhydrous dichloromethane, reflux; (b) NaBH4, MeOH.
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Beilstein J. Org. Chem. 2013, 9, 303–312, doi:10.3762/bjoc.9.35
Graphical Abstract
Figure 1: Examples of pyrrole-containing bioactive compounds.
Scheme 1: Synthesis of Pd–NHC complexes.
Beilstein J. Org. Chem. 2012, 8, 1458–1478, doi:10.3762/bjoc.8.166
Graphical Abstract
Figure 1: Second-order rate constants for reactions of electrophiles with nucleophiles.
Figure 2: Mechanism of amine-catalyzed conjugate additions of nucleophiles [23-28].
Figure 3: Kinetics of the reactions of the iminium ion 3a with the silylated ketene acetal 7a [35].
Figure 4: Laser flash photolytic generation of iminium ions 3a.
Figure 5: Correlations of the reactivities of the iminium ions 3a and 3b toward nucleophiles with the corresp...
Figure 6: Comparison of the electrophilicities of cinnamaldehyde-derived iminium ions 3a–3i.
Figure 7: Nucleophiles used in iminium activated reactions [35,42,44-52].
Figure 8: Counterion effects in electrophilic reactions of iminium ions 3a-X (at 20 °C, silyl ketene acetal 7b...
Figure 9: Comparison of calculated and experimental rate constants of electrophilic aromatic substitutions wi...
Figure 10: Aza-Michael additions of the imidazoles 15 with the iminium ion 3a [58].
Figure 11: Plots of log k2 for the reactions of enamides 17a–17e with the benzhydrylium ions 18a–d in CH3CN at...
Figure 12: Comparison of the nucleophilicities of enamides 17 with those of several other C nucleophiles (solv...
Figure 13: Experimental and calculated rate constants k2 for the reactions of 17b and 17g with 3a and 3b in th...
Figure 14: Comparison between experimental and calculated (Equation 1) cyclopropanation rate constants [64].
Figure 15: Electrostatic activation of iminium activated cyclopropanations with sulfur ylides.
Figure 16: Sulfur ylides inhibit the formation of iminium ions.
Figure 17: Enamine activation [65].
Figure 18: Electrophilicity parameters E for classes of compounds that have been used as electrophilic substra...
Figure 19: Quantification of the nucleophilic reactivities of the enamines 32a–e in acetonitrile (20 °C) [83]; a d...
Figure 20: Proposed transition states for the stereogenic step in proline-catalyzed reactions.
Figure 21: Kinetic evidence for the anchimeric assistance of the electrophilic attack by the carboxylate group....
Figure 22: Differentiation of nucleophilicity and Lewis basicity (in acetonitrile at 20 °C): Rate (left) and e...
Figure 23: NHCs 41, 42, and 43 are moderately active nucleophiles and exceptionally strong Lewis bases (methyl...
Figure 24: Nucleophilic reactivities of the deoxy Breslow intermediates 45 in THF at 20 °C [107].
Figure 25: Comparison of the proton affinities (PA, from [107]) of the diaminoethylenes 47a–c with the methyl catio...
Figure 26: Berkessel’s synthesis of a Breslow intermediate (51, keto tautomer) from carbene 43 [112].
Figure 27: Synthesis of O-methylated Breslow intermediates [114].
Figure 28: Relative reactivities of deoxy- and O-methylated Breslow intermediates [114].
Figure 29: Reactivity scales for electrophiles and nucleophiles relevant for organocatalytic reactions (refere...
Beilstein J. Org. Chem. 2012, 8, 25–49, doi:10.3762/bjoc.8.4
Graphical Abstract
Figure 1: Schematic representation of organic D-π-A system featuring ICT.
Figure 2: Two principal orientations of the imidazole-derived charge-transfer chromophores.
Scheme 1: Common synthetic approach to triarylimidazole-, diimidazole-, and benzimidazole-derived CT chromoph...
Scheme 2: Syntheses of important 4,5-dicyanoimidazole derivatives 1–3 [27-30].
Figure 3: Donor–acceptor triaryl push–pull azoles 4a–h [31,32].
Figure 4: Y-shaped CT chromophores with an extended π-conjugated pathway and various donor and acceptor subst...
Figure 5: Molecular structures of chromophores 9–14 [13,15,37-41].
Figure 6: General structure of 4,5-bis(4-aminophenyl)imidazole-derived chromophores 15a–g with various π-link...
Figure 7: Various orientations of the substituents on the parent lophine π-conjugated backbone (16–19) and th...
Figure 8: Structure and electronic absorption spectra of chromophores 21–26 [12].
Figure 9: Typical D-π-A diimidazole CT chromophore [16-18,50-53].
Figure 10: Typical D-π-D diimidazoles 28–31 [19,54-56] and photochromic diimidazoles 32,33 [57,58].
Scheme 3: Oxidation of 1H-diimidazoles to 2H-diimidazoles (quinoids).
Figure 11: Typical benzimidazoles-derived D-π-A push–pull systems 35–43 [25,62-66].
Figure 12: Structure of benzimidazoles (44–47), imidazophenanthrolines (48–57), imidazophenanthrenes (58–60), ...
Scheme 4: Acidoswitchable NLO-phores 64,65 and ESIPT mechanism [72-74].
Figure 13: General structures of bis(benzimidazole) chromophores 67–71 and pyridinium betaines 72 [75-79].
Figure 14: Overview of 4,5-dicyanoimidazole derivatives investigated by Rasmussen et al. [29,81-94].
Figure 15: 4,5-Dicyanoimidazole-derived chromophores 84–87 [103-106].
Figure 16: Push–pull chromophores 88–93 with systematically extended π-linker [30].
Figure 17: pH-triggered NLO switches 88c–93c [109].
Figure 18: Dibromoolefin 94 and branched chromophores 95–100 [112,113].
Figure 19: Imidazole as a donor–acceptor unit in CT-chromophores 101–111 [20].
Figure 20: Diimidazoles 112–115 used as small electron acceptors in organic solar cells [115,116].
Figure 21: Amino- and hydroxy-functionalized chromophores incorporated into a polymer backbone Rpol [18,50-53,122-124].
Figure 22: Structure of polyphosphazene polymers bearing NLO-phores [125-127] and some other recent examples of nonline...
Figure 23: Epoxy- and silica-based polymers functionalized with 4,5-dicyanoimidazole unit [105,130].
Beilstein J. Org. Chem. 2011, 7, 1584–1601, doi:10.3762/bjoc.7.187
Graphical Abstract
Scheme 1: Stoichiometric and catalytic direct (hetero)arylation of arenes.
Scheme 2: Stille and Negishi cross-coupling methodologies in oxazole series [28,30,31,33,34].
Scheme 3: Stoichiometric direct (hetero)arylation of (benz)oxazole with magnesate bases [35].
Scheme 4: Ohta's pioneering catalytic direct C5-selective pyrazinylation of oxazole [36,37].
Scheme 5: Preparation of pharmaceutical compounds by following the pioneering Ohta protocol [38,39].
Scheme 6: Miura’s pioneering catalytic direct arylations of (benz)oxazoles [40]. aIsolated yield.
Scheme 7: Pd(0)- and Cu(I)-catalyzed direct C2-selective arylation of (benz)oxazoles [41-44].
Scheme 8: Cu(I)-catalyzed direct C2-selective arylations of (benz)oxazoles [40,45-47].
Scheme 9: Copper-free Pd(0)-catalyzed direct C5- and C2-selective arylation of oxazole-4-carboxylate esters [48-50,52].
Scheme 10: Iterative synthesis of bis- and trioxazoles [51].
Scheme 11: Preparation of DPO- and POPOP-analogues [53].
Scheme 12: Pd(0)-catalyzed direct arylation of benzoxazole with aryl chlorides [54].
Scheme 13: Pd(0)-catalyzed direct C2-selective arylation of (benz)oxazoles with bromides and chlorides using b...
Scheme 14: Palladium-catalyzed direct arylation of oxazoles under green conditions; (a) Zhuralev direct arylat...
Scheme 15: Pd(0)-catalyzed C2- and C5-selective (hetero)arylation of oxazole [63].
Scheme 16: Pd(0)-catalyzed C2- and C5-selective (hetero)arylation of ethyl oxazole-4-carboxylate [64].
Scheme 17: Pd(0)-catalyzed direct C4-phenylation of oxazoles; (a) Miura’s procedure [65]; (b) Fagnou’s procedure [66].
Scheme 18: Catalytic cycles for Cu(I)-catalyzed (routeA) and Pd(0)/Cu(I)-catalyzed (route B) direct arylation ...
Scheme 19: Base-assisted, Pd(0)-catalyzed, C2-selective, direct arylation of benzoxazole proposed by Zhuralev [58]...
Scheme 20: Electrophilic substitution-type mechanism proposed by Hoarau [64].
Scheme 21: CMD-proceeding C5-selective direct arylation of oxazole proposed by Strotman and Chobabian [63].
Scheme 22: DFT calculations on methyl oxazole-4-carboxylate and consequently developed methodologies for the P...
Scheme 23: Pd(0)-catalyzed direct arylation of (benz)oxazoles with tosylates and mesylates [71].
Scheme 24: Pd(0)-catalyzed direct arylation of oxazoles with sulfamates [72].
Scheme 25: Pd(II)- and Cu(II)-catalyzed decarboxylative direct C–H coupling of oxazoles with 4- and 5-carboxyo...
Scheme 26: Pd(II)- and Ag(II)-catalyzed decarboxylative direct arylation of (benzo)oxazoles [74]; (a) procedure; (...
Scheme 27: Pd(II)- and Cu(II)-catalyzed direct arylation of benzoxazole with arylboronic acids [76]; (a) procedure...
Scheme 28: Ni(II)-catalyzed direct arylation of benzoxazoles with arylboronic acids under O2 [76]; (a) procedure; ...
Scheme 29: Rhodium-catalyzed direct arylation of benzoxazole [78,79].
Scheme 30: Ni(II)-catalyzed direct arylation of (benz)oxazoles with aryl halides; (a) Itami's procedure [80]; (b) ...
Scheme 31: Dehydrogenative cross-coupling of (benz)oxazoles; (a) Pd(II)- and Cu(II)-catalyzed cross-coupling o...
Beilstein J. Org. Chem. 2011, 7, 668–677, doi:10.3762/bjoc.7.79
Graphical Abstract
Figure 1: Isomeric forms of triazole.
Scheme 1: Copper catalyzed azide–alkyne cycloaddition.
Scheme 2: Ruthenium catalyzed azide–alkyne cycloaddition.
Scheme 3: Copper-sulfate catalyzed azide–alkyne cycloaddition.
Scheme 4: Azide–dimethylbut-2-yne-dioate cycloaddition.
Figure 2: Triazole compound 3 with most potent antifugal activity against various strains [20].
Figure 3: Triazole compounds 4 and 5 showing antifungal activity against Candida albicans [31].
Figure 4: Triazole compound 6 with the highest activity against Aspergillus flavus, Aspergillus versicolor, A...
Figure 5: Triazole compound 7 exhibiting an MIC of 25 µg/mL against Aspergillus niger [33].
Figure 6: Triazole compound 8 showing the most significant activity against Aspergillus niger and Fusarium ox...
Figure 7: Ergosterol biosynthesis inhibitor pathway.
Figure 8: Fluconazole (9).
Figure 9: Itraconazole (10).
Figure 10: Voriconazole (11).
Figure 11: Posaconazole (12).
Figure 12: Ravuconazole (13).
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
Beilstein J. Org. Chem. 2011, 7, 59–74, doi:10.3762/bjoc.7.10
Graphical Abstract
Scheme 1: Synthesis of selective D3 receptor ligands.
Scheme 2: Synthesis of a novel 5-HT1B receptor antagonist.
Scheme 3: Synthesis of A-366833, a selective α4β2 neural nicotinic receptor agonist.
Scheme 4: A new route to oxcarbazepine.
Scheme 5: Synthesis of key intermediates for norepinephrine transporter (NET) inhibitors.
Scheme 6: N-Annulation yielding substituted indole for the synthesis of demethylasterriquinone A1.
Scheme 7: Palladium-catalysed double N-arylation contributing to the synthesis of murrazoline.
Scheme 8: Synthesis of vitamin E amines.
Scheme 9: Improved synthesis of martinellic acid.
Scheme 10: New tariquidar-derived ABCB1 inhibitors.
Scheme 11: β-Carbolin-1-ones as inhibitors of tumour cell proliferation.
Scheme 12: Copper-catalysed synthesis of promazine drugs.
Scheme 13: Palladium-catalysed multicomponent reaction for the synthesis of promazine drugs.
Scheme 14: Key intermediate for imatinib.
Scheme 15: Synthesis of an effective Chek1/KDR kinase inhibitor.
Scheme 16: Macrocyclization as final step of the synthesis of heat shock protein inhibitor.
Scheme 17: Synthesis of N-arylimidazoles.
Scheme 18: Synthesis of benzolactam V8.
Scheme 19: Synthesis of an intermediate for lotrafiban (SB-214857).
Scheme 20: Intermolecular effort towards lotrafiban.
Scheme 21: Synthesis of matrix metalloproteases (MMPs) inhibitor.
Scheme 22: Regioselective 9-N-arylation of purines.
Scheme 23: N-Arylation of adenine and cytosine.
Scheme 24: 9-N-Arylpurines as enterovirus inhibitors.
Scheme 25: Xanthine analogues as kinase inhibitors.
Scheme 26: Synthesis of dual PPARα/γ agonists.
Scheme 27: N-Aryltriazole ribonucleosides with anti-proliferative activity.
Beilstein J. Org. Chem. 2010, 6, 880–921, doi:10.3762/bjoc.6.88
Graphical Abstract
Figure 1: Examples of industrial fluorine-containing bio-active molecules.
Figure 2: CF3(S)- and CF3(O)-containing pharmacologically active compounds.
Figure 3: Hypotensive candidates with SRF and SO2RF groups – analogues of Losartan and Nifedipin.
Figure 4: The variety of the pharmacological activity of RFS-substituted compounds.
Figure 5: Recent examples of compounds containing RFS(O)n-groups [12-18].
Scheme 1: Fluorination of ArSCCl3 to corresponding ArSCF3 derivatives. For references see: a[38-43]; b[41,42]; c[43]; d[44]; e[38-43,45-47]; f[38-43,48,49]; g...
Scheme 2: Preparation of aryl pentafluoroethyl sulfides.
Scheme 3: Mild fluorination of the aryl SCF2Br derivatives.
Scheme 4: HF fluorinations of aryl α,α,β-trichloroisobutyl sulfide at various conditions.
Scheme 5: Monofluorination of α,α-dichloromethylene group.
Scheme 6: Electrophilic substitution of phenols with CF3SCl [69].
Scheme 7: Introduction of SCF3 groups into activated phenols [71-74].
Scheme 8: Preparation of tetrakis(SCF3)-4-methoxyphenol [72].
Scheme 9: The interactions of resorcinol and phloroglucinol derivatives with RFSCl.
Scheme 10: Reactions of anilines with CF3SCl.
Scheme 11: Trifluoromethylsulfanylation of anilines with electron-donating groups in the meta position [74].
Scheme 12: Reaction of benzene with CF3SCl/CF3SO3H [77].
Scheme 13: Reactions of trifluoromethyl sulfenyl chloride with aryl magnesium and -mercury substrates.
Scheme 14: Reactions of pyrroles with CF3SCl.
Scheme 15: Trifluoromethylsulfanylation of indole and indolizines.
Scheme 16: Reactions of N-methylpyrrole with CF3SCl [80,82].
Scheme 17: Reactions of furan, thiophene and selenophene with CF3SCl.
Scheme 18: Trifluoromethylsulfanylation of imidazole and thiazole derivatives [83].
Scheme 19: Trifluoromethylsulfanylation of pyridine requires initial hydride reduction.
Scheme 20: Introduction of additional RFS-groups into heterocyclic compounds in the presence of CF3SO3H.
Scheme 21: Introduction of additional RFS-groups into pyrroles [82,87].
Scheme 22: By-products in reactions of pyrroles with CF3SCl [82].
Scheme 23: Reaction of aromatic iodides with CuSCF3 [93,95].
Scheme 24: Reaction of aromatic iodides with RFZCu (Z = S, Se), RF = CF3, C6F5 [93,95,96].
Scheme 25: Side reactions during trifluoromethylsulfanylation of aromatic iodides with CF3SCu [98].
Scheme 26: Reactions with in situ generated CuSCF3.
Scheme 27: Perfluoroalkylthiolation of aryl iodides with bulky RFSCu [105].
Scheme 28: In situ formation and reaction of RFZCu with aryl iodides.
Figure 6: Examples of compounds obtained using in situ generated RFZCu methodology [94].
Scheme 29: Introduction of SCF3 group into aromatics via difluorocarbene.
Scheme 30: Tetrakis(dimethylamino)ethylene dication trifluoromethyl thiolate as a stable reagent for substitut...
Scheme 31: The use of CF2=S/CsF or (CF3S)2C=S/CsF for the introduction of CF3S groups into fluorinated heteroc...
Scheme 32: One-pot synthesis of ArSCF3 from ArX, CCl2=S and KF.
Scheme 33: Reaction of aromatics with CF3S− Kat+ [115].
Scheme 34: Reactions of activated aromatic chlorides with AgSCF3/KI.
Scheme 35: Comparative CuSCF3/KI and Hg(SCF3)2/KI reactions.
Scheme 36: Me3SnTeCF3 – a reagent for the introduction of the TeCF3 group.
Scheme 37: Sandmeyer reactions with CuSCF3.
Scheme 38: Reactions of perfluoroalkyl iodides with alkali and organolithium reagents.
Scheme 39: Perfluoroalkylation with preliminary breaking of the disulfide bond.
Scheme 40: Preparation of RFS-substituted anilines from dinitrodiphenyl disulfides.
Scheme 41: Photochemical trifluoromethylation of 2,4,6-trimercaptochlorobenzene [163].
Scheme 42: Putative process for the formation of B, C and D.
Scheme 43: Trifluoromethylation of 2-mercapto-4-hydroxy-6-trifluoromethylyrimidine [145].
Scheme 44: Deactivation of 2-mercapto-4-hydroxypyrimidines S-centered radicals.
Scheme 45: Perfluoroalkylation of thiolates with CF3Br under UV irradiation.
Scheme 46: Catalytic effect of methylviologen for RF• generation.
Scheme 47: SO2−• catalyzed trifluoromethylation.
Scheme 48: Electrochemical reduction of CF3Br in the presence of SO2 [199,200].
Scheme 49: Participation of SO2 in the oxidation of ArSCF3−•.
Scheme 50: Electron transfer cascade involving SO2 and MV.
Scheme 51: Four stages of the SRN1 mechanism for thiol perfluoroalkylation.
Scheme 52: A double role of MV in the catalysis of RFI reactions with aryl thiols.
Scheme 53: Photochemical reaction of pentafluoroiodobenzene with trifluoromethyl disulfide.
Scheme 54: N- Trifluoromethyl-N-nitrosobenzene sulfonamide – a source of CF3• radicals [212,213].
Scheme 55: Radical trifluoromethylation of organic disulfides with ArSO2N=NCF3.
Scheme 56: Barton’s S-perfluoroalkylation reactions [216].
Scheme 57: Decarboxylation of thiohydroxamic esters in the presence of C6F13I.
Scheme 58: Reactions of thioesters of trifluoroacetic and trifluoromethanesulfonic acids in the presence of ar...
Scheme 59: Perfluoroalkylation of polychloropyridine thiols with xenon perfluorocarboxylates or XeF2 [222,223].
Scheme 60: Interaction of Xe(OCORF)2 with nitroaryl disulfide [227].
Scheme 61: Bi(CF3)3/Cu(OCOCH3)2 trifluoromethylation of thiophenolate [230].
Scheme 62: Reaction of fluorinated carbanions with aryl sulfenyl chlorides.
Scheme 63: Reaction of methyl perfluoromethacrylate with PhSCl in the presence of fluoride.
Scheme 64: Reactions of ArSCN with potassium and magnesium perfluorocarbanions [237].
Scheme 65: Reactions of RFI with TDAE and organic disulfides [239,240].
Scheme 66: Decarboxylation of perfluorocarboxylates in the presence of disulfides [245].
Scheme 67: Organization of a stable form of “CF3−” anion in the DMF.
Scheme 68: Silylated amines in the presence of fluoride can deprotonate fluoroform for reaction with disulfide...
Figure 7: Other examples of aminomethanols [264].
Scheme 69: Trifluoromethylation of diphenyl disulfide with PhSO2CF3/t-BuOK.
Scheme 70: Amides of trifluoromethane sulfinic acid are sources of CF3− anion.
Scheme 71: Trifluoromethylation of various thiols using “hyper-valent” iodine (III) reagent [279].
Scheme 72: Trifluoromethylation of p-nitrothiophenolate with diaryl CF3 sulfonium salts [280].
Scheme 73: Trifluoromethyl transfer from dibenzo (CF3)S-, (CF3)Se- and (CF3)Te-phenium salts to thiolates [283].
Scheme 74: Multi-stage paths for synthesis of dibenzo-CF3-thiophenium salts [61].
Beilstein J. Org. Chem. 2008, 4, No. 40, doi:10.3762/bjoc.4.40
Graphical Abstract
Scheme 1: Simple copper salt-catalyzed N-arylation reaction of amines, amides, imides and sulfonamides.
Scheme 2: N-arylation reaction of phthalimide with arylboroxine.
Beilstein J. Org. Chem. 2008, 4, No. 23, doi:10.3762/bjoc.4.23
Graphical Abstract
Figure 1: 1: An intuitive prediction regarding the relationship between crude hydrogen bond donor/acceptor di...
Figure 2: Facile syntheses of imidazole carboxamidines from commercial imidazoles and carbodiimides furnished...
Figure 3: The NCNC dihedral angle, θ, between the hydrogen bond donors and acceptors, was assigned values bet...
Figure 4: Stereoview of Dimer 5c. This dimer stacked imidazole rings with R1 pointing in opposite directions.
Figure 5: Stereoview of trimer 6b.
Figure 6: Stereoview of tetramer 9a.
Figure 7: Stereoview of linear hydrogen bond tape 11a.
Figure 8: The calculated (rhf/6-311+g(d,p)) potential energy (kcal/mol) of N,N'-dimethyl-1H-imidazole-1-carbo...
Figure 9: A Flow chart for the calculation of the energies of the n-mers minus the effects of packing and sub...
Figure 10: Icons correspond to those in Figure 8. Crosses indicate structures with aromatic groups. The calculated (rh...
Figure 11: The icon legend is identical to Figure 8 and Figure 10. The Y-axis from Figure 8 energies (θ only) and the X-axis from Figure 10 ener...
Beilstein J. Org. Chem. 2005, 1, No. 8, doi:10.1186/1860-5397-1-8